[{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"BI 1701963","moa":"SOS1","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Mirati Therapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Qiagen","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qiagen \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aadi Bioscience \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Adagrasib","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Qiagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ QIAGEN","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ QIAGEN"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":5.7999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":5.7999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Kura Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":5.7999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":5.7999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zai Lab \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Adagrasib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KRAZATI (adagrasib), a potent oral small-molecule inhibitor of KRASG12C, is indicated in combination with cetuximab for patients with locally advanced or metastatic colorectal cancer.

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 21, 2024

                          Lead Product(s) : Adagrasib,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KRAZATI (adagrasib), a selective oral inhibitor of KRASG12C, is being evaluated with cetuximab for KRASG12C-mutated locally advanced or metastatic colorectal cancer.

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : Adagrasib,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KRAZATI (adagrasib) is a selective oral KRASG12C inhibitor, currently in Phase III trials for treating locally advanced or metastatic non-small cell lung cancer.

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 01, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Krazati (adagrasib) is an oral small-molecule KRAS G12C inhibitor under evaluation for treating KRASG12C-mutated advanced/metastatic non-small cell lung cancer.

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 28, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Krazati (adagrasib) is a selective KRAS G12C inhibitor under evaluation for KRAS G12C-mutated metastatic colorectal cancer.

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 20, 2024

                          Lead Product(s) : Adagrasib,Cetuximab,BMS-986466

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor for advanced non-small cell lung cancer harboring a KRASG12C mutation.

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : $5,800.0 million

                          January 23, 2024

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $5,800.0 million

                          Deal Type : Acquisition

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC).

                          Brand Name : KO-2806

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 02, 2023

                          Lead Product(s) : KO-2806,Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Mirati Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the acquisition, BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor approved by the U.S. FDA for the treatment of patients with advanced non-small cell lung cancer harboring a KRA...

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : $5,800.0 million

                          October 08, 2023

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $5,800.0 million

                          Deal Type : Acquisition

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated ...

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 21, 2023

                          Lead Product(s) : Adagrasib,Cetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated ...

                          Brand Name : Krazati

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 21, 2022

                          Lead Product(s) : Adagrasib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank